1. Perry D, Sperling R, Katz R, Berry, Dilts DM, Hanna D., … & Bens C. (2015). Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Review of Neurotherapeutics, 15(3), 327-333. PMID: 25708309
2. Stephenson D, (plus 14 others) (2015) Charting a path toward combination therapy for Alzheimer’s disease,” Expert Review of Neurotherapeutics, 15(1):107-13. PMID: 25540951
3. Denicoff AM (plus 28 others), (2013) “The NCI-ASCO Cancer Trial Accrual Symposium: Summary and Recommendations,” J of Oncology Practice 9(6): 267-76. PMID:24130252
4. Hirsh BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chriswell K, Schulman KA, Dilts DM, and Abernethy AP (2013) “Characteristics of Oncology Clinical Trials: Insights from a Systematic Analysis of ClinicalTrials.gov,” JAMA Internal Medicine, 173(11):972-979. PMID:23699837.
5. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
6. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
7. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
8. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
9. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
10. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
11. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
12. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
13. Cheney A, Pence K, and Dilts DM, (2014) “Organizational Impacts of Participation in Development of Industry-Level Technology Roadmaps,” 4th IAJC/ISAM Conference Proceedings, Sept, Orlando, FL. http://cd14.ijme.us/itc/
14. Cheng S and Dilts DM (2013) “Building Expertise in The Translational Processes Through Partnerships with Schools of Business” book chapter in Translational Research in Biomedicine, Karger Publishing DOI: 10.1159/000343022
15. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
16. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH (2010) “Clinical Trial Opportunities in Transfusion Medicine: Proceedings of an NHLBI State of the Science Symposium,” role: contributor, Transfusion Medicine Reviews, 24(4): 259-85. PMID: 20851330
17. Pathak SD and Dilts DM (2006) “Investigating evolution in the US healthcare industry,” Decision Sciences Institute (DSI) National Meeting, (November)
18. Pathak, Surya, Dilts DM, and Biswas, Gautam, (2004) “Simulating Growth Dynamics in Complex Adaptive Supply Networks,” Winter Simulation Conference (December), pp: 774-782.
19. Pidduck, Anne B. and Dilts DM. (1999) “Inter-Organizational Structures for Knowledge Sharing,” Proceedings of the ACM SIGCPR 99, pp. 135-137 (http://www.acm.org/pubs/citations/Proc./ cpr/299513/p135-pidduck/)
20. Pidduck, Anne B. and Dilts DM. (1999) “Inter-Organizational Structures for Strategic Advantage,” Information Resources Management Association.
21. Adamson, I. and Dilts DM, (1998) “A Hierarchy of Accounting System Complexity,” Proceedings of the DSI National Meeting,.
22. Dilts DM (1992) “Demonstrating Interfirm Relationships in the Classroom: The Supply Chain Game,” Proceedings of the DSI National Meeting, pp. 9-11.
23. Dilts DM and Wu, W, (1990) “An Intelligent Framework for the Integration of Computer Integrated Manufacturing Data Bases,” Proceedings of the DSI National Meeting, pp. 1702-1705.
24. Dilts D, Cheng S, Cronin K, Fearn P, Feuer E, Friedman S, Kosary C, Lam C, Mariotto A, Negoita S, Petkov V, Penberthy L (2017) “An Innovative Approach to Developing the SEER-Wide Quality Audit Plan,” North American Association of Central Cancer Registries (NAACCR), June.
25. Massett, HA, Dilts, DM, +11 others (2016), “Will a national communication campaign to increase awareness of clinical trials work?” J Clin Oncol 34:15s (suppl; abstr: 6537)
26. Dilts DM, Cheng SK, Stover-Fiscalini A., Kennedy Thompson, C. Hogarth, M, Esserman L, (2014) “Barriers to creating the next-generation cancer registry”, J Clin Oncol 32:15s (suppl; abstr e17682).
27. Hirsch BR, Mitchell A, Cheng SK, Califf RM, Tasneem A, Dilts DM, Abernethy AP (2012) “Improving the impact of clinical research: A systematic analysis of kidney cancer trials” J Clin Oncol 30:15s (suppl; abstr 6051).
28. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Chiswell K, Horton JR, Schulman KA, Dilts DM, Abernethy AP (2012) “The State of the Oncology Clinical Trials Portfolio: Insights from ClinicalTrial.gov”, Society of Clinical Trials Meeting (May).
29. Dilts DM, Peters, C, Stadum, S, Cheng, SK, “Where you stand depends upon where you sit: Alignment of quality measures to strategic intentions,” ASCO’s Quality Care Symposium, 2012.
30. Kethert KH, Cheng SK, Nauman DJ, Dilts DM, Sandler AB, Chui SY (2011) “Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center,” J Clin Oncol 29:15s (suppl; abstr 6052)
31. Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM (2011) “AccrualNet: a novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform,” J Clin Oncol 29 (suppl; abstr e16621)
32. Dilts DM, Cheng SK, Wiltrout RH, Dahut WL, Bronez M, Helman LJ (2011) “Strategic alignment of clinical trials at the National Cancer Institute Center for Cancer Research: Development of the clinical mission and baseline portfolio metrics,” J Clin Oncol 29 (suppl; abstr e16619)
33. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Axis Definitions for CTSA Portfolio Analysis ,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
34. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Evaluation Key Function Committee December 2010 Meeting,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
35. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
36. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Bookman M, Thomas J, and Ostroff J, (2008) “Accrual to Clinical Trials at Selected Comprehensive Cancer Centers,” 26(15S): 6543
37. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Setups in Oncology Clinical Trials: a missing opportunity for improvement,” EurOMA 2008.
38. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
39. Dilts DM (2006) “Applications of OM Techniques in Improving Drug Clinical Trials,” Production and Operations Management Society International Conference, Shanghai, China, June.
40. Dilts DM (2006) “Applications of OM techniques in Improving the Delivery of Healthcare” (Panel presentation) Production and Operations Management Society, Boston, April.
41. Dilts DM (2005) “Practice Variation: The Achilles’ Heel in Quality Cancer Care,” Journal of Clinical Oncology, 23:17(Sept 1): 5881-2 (invited) PMID: 16087953
42. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
43. Ferranti, Lori and Dilts DM (2003) “A Systematic Review of Types and Uses of Medical Registries,” 20th Annual Research Meeting of the Academy of Health. (poster) (June)
44. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
45. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
46. (2015) “Value-based Structures: Centralization and Decentralization”, NIH-Association of Biomolecular Resource Facilities Workshop on Enhancing Efficiency of Research Core Facilities, St Louis, MO(Mar)
47. (2014) “The Future of Clinical Research”, Clinical Trials Advisory Committee, Commonwealth of Australia, Sydney, AUS(Nov)
48. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
49. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
50. (2014) “The Importance of Doing Trials Right While doing the Right Trials,” Ministry of Health, NSW, Australia(August)
51. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
52. (2014) “Integration Metrics: Linking Mission, Science, Resources and Education,” NICHD Division of Intramural Research, Scientific Retreat, Bethesda, MD(Feb).
53. (2014) Overcoming some of the barriers in Clincial Trial Data Access
54. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
55. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
56. (2013) “Consortium or not to Consortium”, ACT-AD National Meeting on Alzheimer’s Research, Washington, DC(May)
57. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
58. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
59. (2012) “Precompetitive Collaboration & Coopetition: Lessons Learned from History and Other Industries,” ACT-AD annual meeting, Bethesda MD(Nov)
60. (2012) “Metrics for Clinical Trials: Lessons Learned”, CTSA Annual Evaluation Meeting, Bethesda MD(Oct)
61. (2012) Pain in the drug supply chain
62. (2011) “Management Principles in Healthcare” Southern Health, Melbourne AUS(Nov) and The Albert Hospital System, Melbourne AUS(Nov)
63. (2011) “Multi-disciplinary, Useful research” Melbourne Operations Management Society(MOMS)(Nov)
64. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
65. (2011) “Precompetitive Collaboration: Lessons from History and Other Industries,” UCSF Accelerating Targeted Cancer Drug-Biomarker Development Conference, San Francisco CA(May)
66. (2011) “Clinical Research as a Complex Adaptive System,” Arizona State University Institute for Complexity, Phoenix, AZ(Mar)
67. (2011) “Mis-Measurement of Quality in IRBs: Thoughts from Other Industries,” 13th annual Subject Protection conference, Schulman Group, Cincinnati Children’s and the University of Kentucky, Cincinnati, OH(Sept).
68. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
69. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
70. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
71. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
72. (2009) “Envisioning the Future: Roadmaps & Roadmapping” keynote address to Radiological Society of North America QIBA Roadmapping committee, Chicago IL(Mar)
73. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
74. (2008) “Building Networks: Observations from Oncology and Non-Medical Industries”, keynote address for the NHLBI Workshop on Sickle Cell Disease. Washington, DC(Oct)
75. (2008) “Impact of Pathways in the Business and Technological World,” keynote address for the NCI Translates, NCI Translational Science Meeting, Washington, DC(Nov).
76. COG Orgranizational Redesign